Edwards Lifesciences (NYSE:EW) Price Target Raised to $95.00 at Truist Financial

Edwards Lifesciences (NYSE:EW) had its price objective hoisted by Truist Financial from $90.00 to $95.00 in a report released on Thursday morning, MarketBeat Ratings reports. The brokerage currently has a hold rating on the medical research company’s stock.

Other analysts also recently issued research reports about the company. Citigroup lifted their price objective on Edwards Lifesciences from $101.00 to $110.00 and gave the stock a “buy” rating in a research note on Wednesday, July 8th. TD Cowen reaffirmed a “buy” rating and set a $104.00 price target (up from $97.00) on shares of Edwards Lifesciences in a research note on Tuesday, June 2nd. Canaccord Genuity Group set a $85.00 price objective on shares of Edwards Lifesciences and gave the company a “hold” rating in a research report on Friday, April 24th. Wolfe Research raised shares of Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 price objective for the company in a research note on Wednesday, April 1st. Finally, Barclays restated an “overweight” rating and issued a $110.00 target price (up from $104.00) on shares of Edwards Lifesciences in a report on Monday, April 27th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and seven have given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $98.95.

Edwards Lifesciences Trading Up 0.7%

Shares of Edwards Lifesciences stock opened at $87.92 on Thursday. Edwards Lifesciences has a twelve month low of $72.30 and a twelve month high of $96.29. The company has a quick ratio of 3.63, a current ratio of 4.42 and a debt-to-equity ratio of 0.06. The business has a 50-day moving average price of $87.22 and a 200-day moving average price of $83.93. The firm has a market cap of $50.63 billion, a price-to-earnings ratio of 46.77, a PEG ratio of 2.19 and a beta of 0.86.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.73 by $0.05. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The company had revenue of $1.65 billion for the quarter, compared to the consensus estimate of $1.60 billion. During the same period in the previous year, the business earned $0.64 earnings per share. The firm’s revenue for the quarter was up 16.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Equities research analysts anticipate that Edwards Lifesciences will post 3 EPS for the current fiscal year.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 619 shares of the business’s stock in a transaction on Friday, July 10th. The shares were sold at an average price of $91.70, for a total transaction of $56,762.30. Following the transaction, the vice president owned 40,034 shares in the company, valued at $3,671,117.80. The trade was a 1.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of the stock in a transaction on Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the completion of the sale, the vice president directly owned 98,611 shares in the company, valued at approximately $8,521,962.62. This represents a 19.01% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 45,577 shares of company stock worth $3,855,527 over the last three months. 0.31% of the stock is owned by insiders.

Institutional Investors Weigh In On Edwards Lifesciences

Several institutional investors have recently made changes to their positions in EW. Investors Research Corp grew its holdings in Edwards Lifesciences by 855.3% during the 2nd quarter. Investors Research Corp now owns 898 shares of the medical research company’s stock valued at $81,000 after purchasing an additional 804 shares during the last quarter. Handelsbanken Fonder AB grew its stake in shares of Edwards Lifesciences by 22.0% during the second quarter. Handelsbanken Fonder AB now owns 1,541,212 shares of the medical research company’s stock valued at $139,418,000 after buying an additional 278,208 shares during the last quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors raised its holdings in shares of Edwards Lifesciences by 37.1% in the second quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors now owns 7,208 shares of the medical research company’s stock worth $652,000 after buying an additional 1,950 shares during the period. Revolve Wealth Partners LLC purchased a new stake in shares of Edwards Lifesciences in the second quarter worth approximately $206,000. Finally, Everpar Advisors LLC bought a new stake in shares of Edwards Lifesciences during the 2nd quarter worth approximately $267,000. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.